Markus Warmuth, Monte Rosa Therapeutics CEO
May 21, 2024 10:35 AM EDT
Financing

With a fresh $100M, Monte Rosa CEO de­tails plans to move sev­er­al mol­e­c­u­lar glues in­to the clin­ic

Andrew Dunn

Senior Biopharma Correspondent

Monte Rosa Ther­a­peu­tics CEO Markus War­muth ex­pects mol­e­c­u­lar glues to make up a new class of drugs with “al­most un­lim­it­ed po­ten­tial” in the long run …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times